Abstract:Although FTY720 may alter migration and homing of lymphocytes via sphingosine-1-phosphate (S1P) receptors, our recent studies indicated that FTY720 directly controls the differentiation of Th1 cells to regulatory T cells (Tregs) by targeting S1P1. However, the pharmacological function of FTY720 in immunological hepatic injury remains unknown. In this study, the role and regulatory signaling pathway of S1P receptor were investigated using a pharmacological approach in immune-mediated hepatic injury (IMH). In the context of IMH, FTY720 significantly ameliorated mortality and hepatic pathology. In FTY720-treated mice, recruited CD11b + Gr1 + myeloid-derived suppressor cells (MDSCs) mediate protection against IMH and are functional suppressive immune modulators that result in fewer IFN-g–producing Th1 cells and more Foxp3 + Tregs. In agreement, FTY720-treated MDSCs promote the reciprocal differentiation between Th1 cells and Tregs in vitro and in vivo. Mechanistically, FTY720 treatment induced inducible NO synthase expression and NO production in MDSCs. Pharmacologic inhibition of inducible NO synthase completely eliminates MDSC suppressive function and eradicates their inducible effects on T cell differentiation. Finally, the mTOR inhibitor, rapamycin, photocopies the effects of FTY720 on MDSCs, implicating mTOR as a downstream effector of S1P1 signaling. This study identifies MDSCs as an essential component that provides protection against IMH following FTY720 or rapamycin treatment, validating the S1P1–mTOR signaling axis as a potential therapeutic target in hepatic injury. L iver diseases are associated with significant mortality and represent a major global health problem. Immune-mediated hepatic injury is involved in liver disease that is triggered by a variety of agents, including autoimmune hepatitis and viral hepatitis (1, 2). T cell–mediated immune responses play a critical role in a variety of liver injuries. Activated CD4 + T cells represent the predominant population of T cells that infiltrate the liver in human autoimmune liver diseases (3–5). The injection of Con A in rodents rapidly induces polyclonal T cell activation, which leads to clinical and histological symptoms of acute hepatitis (6, 7). The liver injury of T cell–mediated immunity in human acute hepatitis mimicked in mice by a delayed-type hypersensitivity to picryl chloride (PIH) (8–12). This hepatic injury is mediated by CD4 + T cells. An imbalance of Th1 cells, regulatory T cells (Tregs), and Th2 cells induces acute liver injury. As well-established experimental mouse models of autoimmune liver disease , Con A–induced hepatitis (CIH) and PIH have been used extensively to study the pathophysiology of immune-mediated hepatic injury. Myeloid-derived suppressor cells (MDSCs) are …

Tpl2 Protects Against Fulminant Hepatitis Through Mobilization of Myeloid-Derived Suppressor Cells.

Tectorigenin Protects Against Experimental Fulminant Hepatic Failure by Regulating the TLR4/mitogen‐activated Protein Kinase and TLR4/nuclear Factor‐κb Pathways and Autophagy

Inhibition of Dot1L Alleviates Fulminant Hepatitis Through Myeloid-Derived Suppressor Cells

Toll-like Receptor 4 Inhibitor TAK-242 Improves Fulminant Hepatitis by Regulating Accumulation of Myeloid-Derived Suppressor Cell.

Short-term Use of MyD88 Inhibitor TJ-M2010-5 Prevents D-Galactosamine/lipopolysaccharide-induced Acute Liver Injury in Mice.

Tumor progression locus 2 ablation suppressed hepatocellular carcinoma development by inhibiting hepatic inflammation and steatosis in mice

Activated NKT Cells Facilitated Functional Switch of Myeloid-Derived Suppressor Cells at Inflammation Sites in Fulminant Hepatitis Mice

Tumor Progression Locus 2 in Hepatocytes Potentiates Both Liver and Systemic Metabolic Disorders in Mice

TPL-2 Regulates Macrophage Lipid Metabolism and M2 Differentiation to Control TH2-Mediated Immunopathology

Tumor Progression Locus 2 Promotes Mouse Plasmacytoid Dendritic Cell Cytokine Secretion and Signaling

Targeting S1P1 Receptor Protects Against Murine Immunological Hepatic Injury Through Myeloid-Derived Suppressor Cells.

Tumor Progression Locus 2 Depletion Inhibits Hepatic Inflammation and Steatosis and Incidence of Hepatocellular Carcinoma

Hepatic RACK1 deficiency protects against fulminant hepatitis through myeloid-derived suppressor cells

Tumor Progression Locus 2 (tpl2) Kinase Promotes Chemokine Receptor Expression and Macrophage Migration During Acute Inflammation

TREM2 protects against inflammation by regulating the release of mito-DAMPs from hepatocytes during liver fibrosis

Kupffer-cell-expressed transmembrane TNF-α is a major contributor to lipopolysaccharide and D-galactosamine-induced liver injury

The protective role of myeloid-derived suppressor cells in concanavalin A-induced hepatic injury

Expression of B and T Lymphocyte Attenuator (BTLA) in Macrophages Contributes to the Fulminant Hepatitis Caused by Murine Hepatitis Virus Strain-3

Suppression of liver injury through inhibition of MyD88 signaling in a mouse model of fulminant hepatitis by 18β-glycyrrhetinic acid (142.11)

Interleukin-6 Induces Gr-1+Cd11b+Myeloid Cells To Suppress Cd8+T Cell-Mediated Liver Injury In Mice

Phellinus linteus activates Treg cells via FAK to promote M2 macrophage polarization in hepatocellular carcinoma